Human Epidermal Growth Factor Receptor 2 Gastric Cancer: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Yasushi Sato
,
Koichi Okamoto
,
Yoshifumi Kida
,
Yasuhiro Mitsui
,
Yutaka Kawano
,
Masahiro Sogabe
,
Hiroshi Miyamoto
,
Tetsuji Takayama

Gastric cancer (GC) is one of the most clinically challenging cancers worldwide. New molecular-targeted agents and immunotherapy have markedly improved GC prognosis. Human epidermal growth factor receptor 2 (HER2) expression is a key biomarker in first-line chemotherapy for unresectable advanced GC. Further, the addition of trastuzumab to cytotoxic chemotherapy has extended the overall survival of patients with HER2-positive advanced GC. In HER2-negative GC, the combination of nivolumab, an immune checkpoint inhibitor, and a cytotoxic agent has been demonstrated to prolong the overall survival of GC patients. Ramucirumab and trifluridine/tipiracil, which are second- and third-line treatments for GC, and trastuzumab deruxtecan, an antibody–drug conjugate for HER2-positive GC, have been introduced in clinics. New promising molecular-targeted agents are also being developed, and combination therapy comprising immunotherapy and molecular-targeted agents is expected.

  • gastric cancer
  • biomarker
  • HER2

1. Introduction

In 2018, more than one million new cases of GC were diagnosed, and more than 782,000 deaths were recorded worldwide [1]. The highest mortality rates from GC have been reported in East Asia, including Japan, Korea, and China [2], and the lowest rates have been reported in North America. The mortality rate is mainly dependent on the rate of Helicobacter pylori (HP) infection, as HP infection is a known dominant cause of GC [3]. Owing to the improved treatment of HP, the rate of GC has decreased [4][5]. However, the proportion of proximal GCs, which often lead to a poor prognosis, is increasing [6]. The 5-year survival rate for GC is 60% or higher in Japan [7] and Korea [8], where more than half of GC patients are diagnosed at an early stage through well-organized population screening programs [9][10]. In contrast, GC is often diagnosed at an advanced stage in most Western patients. Notably, the biological nature of GC and differences in therapeutic quality between Eastern and Western countries may affect treatment outcomes [11][12][13].
In terms of the management of localized operable disease, marked disparities between the East and West regarding surgical procedures [14] and their outcomes result in sizeable geographical variation in the preferred adjuvant treatment for localized GC [15]. For example, adjuvant chemoradiotherapy (CRT) is commonly used following D0/1 surgery for patients with GC in the US [16], and an approach with intensive combination chemotherapy administered before and after surgery (perioperative) is preferable in the UK [17]. In East Asia, adjuvant oral fluoropyrimidine-based chemotherapy following D2 resection is considered the gold standard [18].

2. First-Line HER2-Negative Gastric Cancer

2.1. Doublet Chemotherapy

The Asian, US, and European guidelines recommend a regimen of oral or intravenous injection of fluoropyrimidine combined with platinum as the palliative first-line chemotherapy for HER2-negative GC [19][20][21]. The efficacy of cisplatin + S-1 (SP) or capecitabine (XP) doublet combination therapy has been demonstrated by the results of several phase III trials, including the SPIRITS study and JCOG 9912 study [22][23][24]. Among the platinum agents, cisplatin has been mainly used; however, its strong gastrointestinal toxicity, nephrotoxicity, and other side effects have become problematic; thus, other platinum agents have been investigated. In particular, SOX (S-1 + oxaliplatin) and XELOX (oxaliplatin + capecitabine) regimens containing oxaliplatin are recommended as they are easier to administer than SP and XP and do not require hydration. This recommendation is based on evidence obtained from the REAL-2 trial, which revealed that capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin [25]. In fact, the G-SOX study demonstrated that SOX is as effective as FP and has a favorable safety profile [26].
Interestingly, in the GO2 phase III trial, the XELOX regimen with a 60% dose reduction from the standard dose was demonstrated to be less toxic and non-inferior in terms of progression-free survival (PFS) in elderly and frail patients [27]. In addition, the combination of 5-FU/levofolinate (LV) and oxaliplatin (FOLFOX) has demonstrated efficacy and is particularly useful in patients with intestinal obstruction or other difficulties with oral intake [28][29]. S-1 plus docetaxel is conditionally recommended in Japan, as the START trial highlighted its OS superiority over S-1 monotherapy in patients who cannot receive platinum-containing regimens [30].

2.2. Triple Chemotherapy

There are divided views on the three-drug combination therapy. A phase III V325 trial in the U.S. and Europe revealed the superiority of docetaxel/cisplatin/5-fluorouracil (DCF) triple therapy, in which docetaxel was added to 5FU plus cisplatin infusion [31]. However, this three-drug combination was not recommended in Asian guidelines owing to its high toxicity, which was not balanced with efficacy and was only recommended for a small number of tolerable patients. Recently, in Japan, the triple combination of docetaxel, cisplatin, and S-1 (DCS) was compared to SP in a phase III trial (JCOG1013) following the results of a promising phase II trial [32][33]; however, no OS benefit was found [34]. As a result, triple-drug combination therapy, including taxanes, is not currently recommended as a first-line therapy in Japan. There are many criticisms that the study did not employ an appropriate dosage regimen and ultimately did not achieve satisfactory results. Several studies have reported the usefulness of triple-drug combination therapy in cases where conversion therapy is intended [35][36].

2.3. Immunotherapy

In recent years, ICIs have been introduced as a new standard of care for several malignancies, including advanced GC, and have demonstrated good clinical efficacy [37]. To date, the KEYNOTE-062, ATTRACTION-4, and CheckMate 649 trials serve as the major trials that used ICI as the primary treatment for GC. In the KEYNOTE-062 trial, 763 patients (69% with GC) were randomized to receive pembrolizumab alone, pembrolizumab plus chemotherapy (cisplatin/5-FU or capecitabine), and chemotherapy plus placebo as first-line treatment for HER2-negative and PD-Ll-positive (combined positive score (CPS) ≥ 1) unresectable advanced or recurrent GC and esophagogastric junction cancer [38]. In patients with PD-L1 CPS ≥ 1, pembrolizumab monotherapy was non-inferior to chemotherapy (median OS 10.6 vs. 11.1 months (HR, 0.91; 99.2% CI, 0.69–1.18; noninferiority margin, 1.2)) but prolonged OS vs. chemotherapy in patients with CPS ≥ 10 (median OS 17.4 vs. 10.8 months, HR 0.69 (95% CI 0.49–0.97)). In particular, in the group of patients with PD-L1 CPS ≥ 1 and MSI-high tumors, the survival benefit was enhanced with pembrolizumab (HR, 0.29; 95% CI, 0.11–0.81) and pembrolizumab plus chemotherapy (HR, 0.37; 95% CI, 0.14–0.97) vs. chemotherapy, demonstrating the benefit of pembrolizumab in MSI-H tumors [38].
ATTRACTION-4 is a phase II/III trial conducted in Japan, Korea, and Taiwan [39]. In the open-label section, the superiority of nivolumab plus chemotherapy (SOX or oxaliplatin + capecitabine [CapeOX]) over chemotherapy as a first-line treatment for unresectable advanced or recurrent GC and esophagogastric junction cancer was verified. However, no significant difference was found for the other primary endpoint, OS (median OS: 17.45 months vs. 17.15 months, HR: 0.90, 95% CI: 0.75–1.08, p = 0.257), which is presumably because many patients received subsequent treatments or additional immunotherapy. The CheckMate 649 trial, a large, randomized, phase III study of 1,581 patients (24% Asian, 76% non-Asian, 100% adenocarcinoma) was conducted worldwide to analyze the superiority of nivolumab plus chemotherapy over chemotherapy or nivolumab plus ipilimumab [40][41]. Sixty percent (n = 955) of these patients had a PD-L1 CPS score ≥ 5. The primary endpoints of OS (median OS 14.4 vs. 11.1 months (HR 0.71 (98.4% CI (0.59–0.86)), p < 0.0001) and PFS (median PFS: 7.7 months vs. 6.0 months, HR: 0.68, 98% CI: 0.56–0.85, p < 0.0001) revealed the superiority of nivolumab plus chemotherapy. In addition, for OS, a statistically significant difference was found between CPS ≥ 1 patients (median OS: 14.0 months vs. 11.3 months, HR: 0.77, 99.3% CI: 0.64–0.92, p = 0.0001) and the overall population (median OS: 13.8 months vs. 11.6 months, HR: 0.80,99.3% CI: 0·68–0·94, p = 0·0002).
The PFS results also highlighted the superiority of nivolumab plus chemotherapy for CPS ≥ 1 cases and the overall population. The overall response rate (ORR) of patients with a CPS ≥ 5 was 60% vs. 45% (p < 0.0001), with a significantly higher value obtained in the nivolumab plus chemotherapy arm. Furthermore, an improved ORR was achieved in the nivolumab plus chemotherapy arm across all CPS subgroups, with patients with PD-L1 CPS ≥ 5 and MSI-H achieving a benefit, especially when administered the combination with immunotherapy. The combination of nivolumab and ipilimumab without chemotherapy had no clear OS benefit compared to chemotherapy alone. Based on these results, nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma, regardless of PD-L1 CPS status, was approved in the US, Taiwan, and Japan. In Europe, nivolumab plus chemotherapy has been approved for patients with a PD-L1 CPS of ≥ 5.

3. First-Line HER2-Positive Gastric Cancer

3.1. HER2-Targeted Therapy

HER2, also called ERBB2, is a receptor tyrosine protein kinase that is involved in cell proliferation through signaling pathways, such as RAS/RAF/MEK/ERK, PI3K/AKT/mTOR pathways, etc. [42]. HER2-positive tumors show amplification of the HER2 gene, which is commonly associated with protein overexpression, leading to tumorigenesis in GC [43]. Although only 15–20% of GC cases are HER2-positive [44], the clinical efficacy of trastuzumab, a HER2-targeted therapy, has been established for HER2-positive advanced GC. Trastuzumab is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor and inhibits the HER2 signaling pathway. The multicenter phase III ToGA trial revealed that trastuzumab plus cisplatin and fluoropyrimidine significantly improved the survival of patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma compared with that of patients treated with chemotherapy alone (median OS 13.8 vs. 11.1 months, HR 0.74, 95% CI 0.0–0.91; p = 0.0046). In a post-hoc subgroup analysis, the HER-2 overexpression (IHC3+ or IHC2+ and FISH-positive) showed an improvement in OS (median OS 16.0 vs. 11.8 months, HR 0.65, 95% CI 0.51–0.83; p = 0.036) [22].
Following the success of the ToGA trial, several randomized phase III trials evaluated the efficacy of other HER2-targeted therapies in patients with HER2-positive advanced gastric and gastroesophageal junction cancers [45][46]: first-line treatment with lapatinib + capecitabine + oxaliplatin (TRIO-013/LOGiC) [47], pertuzumab and trastuzumab + fluoropyrimidine + cisplatin (JACOB) [48], second-line treatment with lapatinib + paclitaxel (Tytan) [49], and T-DM1 (GATSBY) [50]. However, none of these treatments could improve the clinical outcomes of patients with HER2-positive GC. Several mechanisms have been proposed to cause resistance to HER2-targeted therapies, including (1) the intratumor heterogeneity of HER2, (2) aberrant activation of the PIK3CA signaling pathway (a downstream signal of HER2), and (3) simultaneous amplification of EGFR, MET, and CCNE1 [45].

3.2. Anti-PD-1 Antibody Plus HER2-Targeted Therapy

In a HER2-positive immunocompetent mouse model, anti-PD-1 antibodies have been reported to significantly improve the antitumor activity of trastuzumab by enhancing antibody-dependent cellular cytotoxicity (ADCC) [51]. A phase II trial evaluating the efficacy of trastuzumab plus pembrolizumab in combination with chemotherapy revealed very promising results, with a median PFS of 13.0 months (95% CI, 8.6–NA) and median OS of 27.2 months (95% CI 18.8–NA) [52]. The phase III KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy revealed a statistically significant increase of 22.7% in the ORR in the pembrolizumab group compared to the placebo group (77.4% vs. 51.9%, p = 0.00006) [53]. The pembrolizumab group also displayed more profound responses than the placebo group (median change from baseline: 65% vs. 49%; 80% or ≥80% decrease from baseline: 32.3% vs. 14.8%). Further, more complete responses were observed in the pembrolizumab group than in the placebo group (11.3% vs. 3.1%). These interim results for KEYNOTE-811 led to the expedited FDA approval of the addition of pembrolizumab to trastuzumab and chemotherapy as the first-line treatment of patients with HER2-positive advanced GC. The KEYNOTE-811 trial demonstrated that the addition of ICIs to molecularly targeted therapy may be another potentially efficient strategy to overcome HER2 resistance in GC [53].

4. Second-Line and Subsequent Chemotherapy

Several studies have shown that the administration of taxane or irinotecan results in higher survival rates than best supportive care as a second-line chemotherapy for GC patients with adequate performance status [54][55][56][57]. In addition, the efficacy of the anti-vascular endothelial growth factor receptor (VEGFR)-2 monoclonal antibody, ramucirumab, was proven in the REGARD and RAINBOW randomized phase III trials [58][59]. In the multicenter randomized phase III REGARD trial [59], patients with advanced gastric and gastroesophageal junction cancers who progressed after first-line chemotherapy were randomized to receive ramucirumab or a placebo. The median OS was 5.2 months for ramucirumab and 3.8 months for the placebo (p = 0.047). The randomized phase III RAINBOW trial evaluated paclitaxel with or without ramucirumab in patients with advanced gastric and gastroesophageal junction cancers who had progressed after primary chemotherapy [58]. Patients who received ramucirumab plus paclitaxel had significantly longer median OS (9.63 months) than patients receiving paclitaxel alone (7.36 months, p < 0.0001); the median PFS was 4.4 and 2.86 months, respectively; and the ORR was 6% for paclitaxel alone versus 28% for ramucirumab plus paclitaxel (p = 0.0001).
The KEYNOTE-061 trial comparing pembrolizumab alone with paclitaxel failed to meet its primary endpoint (superior OS for patients with PD-L1 CPS ≥ 1) for patients with advanced gastric and gastroesophageal junction cancers who progressed after first-line chemotherapy. However, pembrolizumab-treated patients with PD-L1 CPS ≥ 10 had superior survival rates compared to patients with PD-L1 CPS ≥ 1 [60]. Paclitaxel plus ramucirumab is generally recommended based on the results of the RAINBOW study and is currently administered in many cases. As pembrolizumab is highly effective in patients with MSI-H, pembrolizumab must be used appropriately via the performance of the MSI test [61].
Recently, several new drugs have been developed as treatment options for ineffective secondary chemotherapy. The ATTRACTION-2 trial, a phase III study that sought to evaluate the efficacy of nivolumab in GC after third-line treatment [62], revealed the superiority of nivolumab over a placebo in OS (nivolumab vs. placebo, median 5.26 months vs. 4.14 months, HR 0.62, 95%CI 0.50–0.75). Notably, the response rate to nivolumab was 11.9%, but the OS in responders was very long (26.68 months). However, the effectiveness of nivolumab in combination with chemotherapy as the first-line treatment for HER2-negative GC has been demonstrated, which may reduce the possibility of using nivolumab as a third-line therapy. A phase III study (TAGS study) was conducted to determine the efficacy of trifluridine/tipiracil (FTD/TPI) as a third-line or later drug and revealed the superiority of FTD/TPI over a placebo in terms of OS (FTD/TPI vs. placebo, median 5.7 months vs. 3.6 months, HR 0.69, 95% CI 0.56–0.85) [63]. Of note, grade 3 or higher neutropenia was observed in 34% of patients, whereas febrile neutropenia was only observed in 2% of patients. FTD/TPI is an oral drug. As many patients with GC have poor oral intake, it is important to administer FTD/TPI when oral intake is still possible.
As mentioned above, no drug has demonstrated efficacy in HER2-targeted therapy for GC, except trastuzumab, as a first-line therapy. A phase II study (DESTINY-Gastric01 study) was conducted to explore the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive GC. T-DXd displayed efficacy for the first time as a HER2-targeted therapy after second-line treatment. The DESTINY-Gastric01 trial randomized patients 2:1 to receive T-DXd or chemotherapy [64]. The efficacy of T-DXd was very high, with an ORR of 51% for T-DXd and 14% for chemotherapy (p < 0.001). Further, 9% of patients (11/119 patients) had complete response to T-DXd. The OS and PFS results were also promising with T-DXd (T-DXd vs. chemotherapy, median OS 12.5 vs. 8.4 months, HR 0.59, 95% CI 0.39–0.88; median PFS 5.6 vs. 3.5 months, HR 0.47, 95% CI 0.31–0.71). The most frequent grade 3 or higher adverse events were neutropenia (51%), anemia (38%), leukopenia (21%), and anorexia (17%). In addition, febrile neutropenia was observed in six patients and drug-induced pneumonia was observed in 10% (12/125) of patients. Although T-DXd-related interstitial lung disease is an adverse event requiring caution, it is considered a manageable adverse event with nine cases of grade 1/2, two cases of grade 3, and one case of grade 4 recorded. T-DXd is preferred over nivolumab as a third-line therapy for HER2-positive patients owing to its high therapeutic efficacy.

This entry is adapted from the peer-reviewed paper 10.3390/jcm12041336

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
  2. Rahman, R.; Asombang, A.W.; Ibdah, J.A. Characteristics of gastric cancer in Asia. World J. Gastroenterol. 2014, 20, 4483–4490.
  3. Uemura, N.; Okamoto, S.; Yamamoto, S.; Matsumura, N.; Yamaguchi, S.; Yamakido, M.; Taniyama, K.; Sasaki, N.; Schlemper, R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345, 784–789.
  4. Arnold, M.; Park, J.Y.; Camargo, M.C.; Lunet, N.; Forman, D.; Soerjomataram, I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends until 2035. Gut 2020, 69, 823–829.
  5. Ito, M.; Sugiyama, A.; Mino, M.; Kodama, M.; Nagaoki, Y.; Abe, K.; Imada, H.; Ouoba, S.E.B.; Ko, K.; Akita, T. Prevalence of Helicobacter pylori infection in the general population evaluated in a resident-register-based epidemiological study. J. Gastroenterol. 2022, 57, 540–546.
  6. Pacelli, F.; Papa, V.; Caprino, P.; Sgadari, A.; Bossola, M.; Doglietto, G.B. Proximal compared with distal gastric cancer: Multivariate analysis of prognostic factors. Am. Surg. 2001, 67, 697–703.
  7. Hamashima, C.; Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Updated version of the Japanese Guidelines for Gastric Cancer Screening. Jpn. J. Clin. Oncol. 2018, 48, 673–683.
  8. Oh, C.M.; Won, Y.J.; Jung, K.W.; Kong, H.J.; Cho, H.; Lee, J.K.; Lee, D.H.; Lee, K.H.; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2013. Cancer Res. Treat. 2016, 48, 436–450.
  9. Pasechnikov, V.; Chukov, S.; Fedorov, E.; Kikuste, I.; Leja, M. Gastric cancer: Prevention, screening, and early diagnosis. World J. Gastroenterol. 2014, 20, 13842–13862.
  10. Ajani, J.A.; Lee, J.; Sano, T.; Janjigian, Y.Y.; Fan, D.; Song, S. Gastric adenocarcinoma. Nat. Rev. Dis. Prim. 2017, 3, 17036.
  11. Machlowska, J.; Baj, J.; Sitarz, M.; Maciejewski, R.; Sitarz, R. Gastric cancer epidemiology, risk factors, classification, genomic characteristics, and treatment strategies. Int. J. Mol. Sci. 2020, 21, 4012.
  12. Etemadi, A.; Safiri, S.; Sepanlou, S.G.; Ikuta, K.; Bisignano, C.; Shakeri, R.; Amani, M.; Fitzmaurice, C.; Nixon, M.R.; Abbasi, N. Global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020, 5, 42–54.
  13. Onoyama, T.; Ishikawa, S.; Isomoto, H. Gastric cancer genomics: Review of literature. J. Gastroenterol. 2022, 57, 505–516.
  14. Ueno, T.; Iida, M.; Yoshino, S.; Takeda, S.; Kubota, H.; Higashida, M.; Oka, Y.; Tsuruta, A.; Matsumoto, H.; Nagano, H. East versus West: Differences in surgical management in Asia compared with Europe and North America. Surg. Clin. N. Am. 2017, 97, 453–466.
  15. Russo, A.; Li, P.; Strong, V.E. Differences in the multimodal treatment of gastric cancer: East versus West. J. Surg. Oncol. 2017, 115, 603–614.
  16. Schernberg, A.; Rivin Del Campo, E.; Rousseau, B.; Matzinger, O.; Loi, M.; Maingon, P.; Huguet, F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin. Transl. Radiat. Oncol. 2018, 10, 13–22.
  17. Fong, C.; Johnston, E.; Starling, N. Neoadjuvant and adjuvant therapy approaches to gastric cancer. Curr. Treat Options Oncol. 2022, 23, 1247–1268.
  18. Kurokawa, Y.; Sasako, M. Asian perspectives on the surgical and adjuvant management of esophagogastric cancer. Surg. Oncol. Clin. N. Am. 2017, 26, 213–224.
  19. NCCN. Clinical Practice Guidelines in Oncology (NCCN Gastric Cancer. NCCN Clin. Pract. Guidel. Oncol. 2022, 7, 933–938.
  20. Smyth, E.C.; Verheij, M.; Allum, W.; Cunningham, D.; Cervantes, A.; Arnold, D.; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 2016, 27, v38–v49.
  21. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2018 (5th edition). Gastric Cancer 2021, 24, 1–21.
  22. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 2010, 376, 687–697.
  23. Koizumi, W.; Narahara, H.; Hara, T.; Takagane, A.; Akiya, T.; Takagi, M.; Miyashita, K.; Nishizaki, T.; Kobayashi, O.; Takiyama, W.; et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008, 9, 215–221.
  24. Boku, N.; Yamamoto, S.; Fukuda, H.; Shirao, K.; Doi, T.; Sawaki, A.; Koizumi, W.; Saito, H.; Yamaguchi, K.; Takiuchi, H.; et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomized phase 3 study. Lancet Oncol. 2009, 10, 1063–1069.
  25. Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A.R.; et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008, 358, 36–46.
  26. Yamada, Y.; Higuchi, K.; Nishikawa, K.; Gotoh, M.; Fuse, N.; Sugimoto, N.; Nishina, T.; Amagai, K.; Chin, K.; Niwa, Y.; et al. A phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann. Oncol. 2015, 26, 141–148.
  27. Hall, P.S.; Swinson, D.; Cairns, D.A.; Waters, J.S.; Petty, R.; Allmark, C.; Ruddock, S.; Falk, S.; Wadsley, J.; Roy, R.; et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: The GO2 Phase 3 randomized clinical trial. JAMA Oncol. 2021, 7, 869–877.
  28. Shah, M.A.; Bang, Y.J.; Lordick, F.; Alsina, M.; Chen, M.; Hack, S.P.; Bruey, J.M.; Smith, D.; McCaffery, I.; Shames, D.S.; et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without Onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial. JAMA Oncol. 2017, 3, 620–627.
  29. Yoon, H.H.; Bendell, J.C.; Braiteh, F.S.; Firdaus, I.; Philip, P.A.; Cohn, A.L.; Lewis, N.; Anderson, D.M.; Arrowsmith, E.; Schwartz, J.D.; et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial. Ann. Oncol. 2016, 27, 2196–2203.
  30. Koizumi, W.; Kim, Y.H.; Fujii, M.; Kim, H.K.; Imamura, H.; Lee, K.H.; Hara, T.; Chung, H.C.; Satoh, T.; Cho, J.Y.; et al. Addition of docetaxel to S-1 without platinum prolongs the survival of patients with advanced gastric cancer: A randomized study (START). J. Cancer Res. Clin. Oncol. 2014, 140, 319–328.
  31. Van Cutsem, E.; Moiseyenko, V.M.; Tjulandin, S.; Majlis, A.; Constenla, M.; Boni, C.; Rodrigues, A.; Fodor, M.; Chao, Y.; Voznyi, E.; et al. A phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J. Clin. Oncol. 2006, 24, 4991–4997.
  32. Sato, Y.; Takayama, T.; Sagawa, T.; Takahashi, Y.; Ohnuma, H.; Okubo, S.; Shintani, N.; Tanaka, S.; Kida, M.; Sato, Y.; et al. A phase II study of S-1, docetaxel, and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother. Pharmacol. 2010, 66, 721–728.
  33. Koizumi, W.; Nakayama, N.; Tanabe, S.; Sasaki, T.; Higuchi, K.; Nishimura, K.; Takagi, S.; Azuma, M.; Ae, T.; Ishido, K.; et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother. Pharmacol. 2012, 69, 407–413.
  34. Yamada, Y.; Boku, N.; Mizusawa, J.; Iwasa, S.; Kadowaki, S.; Nakayama, N.; Azuma, M.; Sakamoto, T.; Shitara, K.; Tamura, T.; et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): An open-label, phase 3, randomized controlled trial. Lancet Gastroenterol. Hepatol. 2019, 4, 501–510.
  35. Sato, Y.; Ohnuma, H.; Nobuoka, T.; Hirakawa, M.; Sagawa, T.; Fujikawa, K.; Takahashi, Y.; Shinya, M.; Katsuki, S.; Takahashi, M.; et al. Conversion therapy for inoperable advanced gastric cancer patients treated with docetaxel, cisplatin, and S-1 (DCS) chemotherapy: A multi-institutional retrospective study. Gastric Cancer 2017, 20, 517–526.
  36. Ohnuma, H.; Sato, Y.; Onoyama, N.; Hamaguchi, K.; Hayasaka, N.; Sato, M.; Murase, K.; Takada, K.; Miyanishi, K.; Murakami, T.; et al. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matching analysis. J. Cancer Res. Clin. Oncol. 2021, 147, 2385–2396.
  37. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibodies in cancer. N. Engl. J. Med. 2012, 366, 2443–2454.
  38. Shitara, K.; Van Cutsem, E.; Bang, Y.J.; Fuchs, C.; Wyrwicz, L.; Lee, K.W.; Kudaba, I.; Garrido, M.; Chung, H.C.; Lee, J.; et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs. chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 Phase 3 randomized clinical trial. JAMA Oncol. 2020, 6, 1571–1580.
  39. Kang, Y.-K.; Chen, L.-T.; Ryu, M.-H.; Oh, D.-Y.; Oh, S.C.; Chung, H.C.; Lee, K.-W.; Omori, T.; Shitara, K.; Sakuramoto, S.; et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastrooesophageal junction cancer (ATTRACTION-4): A randomized, multicenter, double-blind, placebo-cont. Lancet Oncol. 2022, 23, 234–247.
  40. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A.C. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (CheckMate 649): A randomized, open-label, phase 3 trial. Lancet 2021, 398, 27–40.
  41. Shitara, K.; Ajani, J.A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.C.; et al. Nivolumab plus chemotherapy or ipilimumab in gastro-esophageal cancer. Nature 2022, 603, 942–948.
  42. Moasser, M.M. The oncogene HER2 has signaling and transforming functions, and plays a role in human cancer pathogenesis. Oncogene 2007, 26, 6469–6487.
  43. Meric-Bernstam, F.; Johnson, A.M.; Dumbrava, E.E.I.; Raghav, K.; Balaji, K.; Bhatt, M.; Murthy, R.K.; Rodon, J.; Piha-Paul, S.A. Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer. Clin. Cancer Res. 2019, 25, 2033–2041.
  44. Van Cutsem, E.; Bang, Y.J.; Feng-Yi, F.; Xu, J.M.; Lee, K.W.; Jiao, S.C.; Chong, J.L.; López-Sanchez, R.I.; Price, T.; Gladkov, O.; et al. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancers. Gastric Cancer 2015, 18, 476–484.
  45. Mitani, S.; Kawakami, H. Emerging targeted therapies for HER2 positive gastric cancer that can overcome trastuzumab resistance. Cancers 2020, 12, 400.
  46. Siena, S.; Marsoni, S.; Sartore-Bianchi, S. Breaking barriers in HER2+ cancers. Cancer Cell 2020, 38, 317–319.
  47. Hecht, J.R.; Bang, Y.J.; Qin, S.K.; Chung, H.C.; Xu, J.M.; Park, J.O.; Jeziorski, K.; Shparyk, Y.; Hoff, P.M.; Sobrero, A.; et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—A randomized Phase III trial. J. Clin. Oncol. 2016, 34, 443–451.
  48. Tabernero, J.; Hoff, P.M.; Shen, L.; Ohtsu, A.; Shah, M.A.; Cheng, K.; Song, C.; Wu, H.; Eng-Wong, J.; Kim, K.; et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastroesophageal junction cancer (JACOB): Final analysis of a double-blind, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2018, 19, 1372–1384.
  49. Satoh, T.; Xu, R.H.; Chung, H.C.; Sun, G.P.; Doi, T.; Xu, J.M.; Tsuji, A.; Omuro, Y.; Li, J.; Wang, J.W.; et al. Lapatinib plus paclitaxel versus paclitaxel alone in second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN, a randomized phase III study. J. Clin. Oncol. 2014, 32, 2039–2049.
  50. Thuss-Patience, P.C.; Shah, M.A.; Ohtsu, A.; Van Cutsem, E.; Ajani, J.A.; Castro, H.; Mansoor, W.; Chung, H.C.; Bodoky, G.; Shitara, K.; et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GATSBY): An international randomized, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017, 18, 640–653.
  51. Stagg, J.; Loi, S.; Divisekera, U.; Ngiow, S.F.; Duret, H.; Yagita, H.; Teng, M.W.; Smyth, M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 2011, 108, 7142–7147.
  52. Janjigian, Y.Y.; Maron, S.B.; Chatila, W.K.; Millang, B.; Chavan, S.S.; Alterman, C.; Chou, J.F.; Segal, M.F.; Simmons, M.Z.; Momtaz, P.; et al. First-line pembrolizumab and trastuzumab in HER2-positive esophageal, gastric, or gastroesophageal junction cancer: An open-label, single-arm, phase 2 trial. Lancet Oncol. 2020, 21, 821–831.
  53. Janjigian, Y.Y.; Kawazoe, A.; Yañez, P.; Li, N.; Lonardi, S.; Kolesnik, O.; Barajas, O.; Bai, Y.; Shen, L.; Tang, Y.; et al. KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021, 600, 727–730.
  54. Thuss-Patience, P.C.; Kretzschmar, A.; Bichev, D.; Deist, T.; Hinke, A.; Breithaupt, K.; Dogan, Y.; Gebauer, B.; Schumacher, G.; Reichardt, P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer Oxf. Engl. 2011, 47, 2306–2314.
  55. Kang, J.H.; Lee, S.I.; Lim, D.H.; Park, K.W.; Oh, S.Y.; Kwon, H.C.; Hwang, I.G.; Lee, S.C.; Nam, E.; Shin, D.B.; et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 2012, 30, 1513–1518.
  56. Roy, A.C.; Park, S.R.; Cunningham, D.; Kang, Y.K.; Chao, Y.; Chen, L.T.; Rees, C.; Lim, H.Y.; Tabernero, J.; Ramos, F.J.; et al. A randomized phase II study of PEP02 (MM-398), irinotecan, or docetaxel as second-line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Ann. Oncol. 2013, 24, 1567–1573.
  57. Ford, H.E.R.; Marshall, A.; Bridgewater, J.A.; Janowitz, T.; Coxon, F.Y.; Wadsley, J.; Mansoor, W.; Fyfe, D.; Madhusudan, S.; Middleton, G.W.; et al. Docetaxel versus active symptom control for refractory esophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomized controlled trial. Lancet Oncol. 2014, 15, 78–86.
  58. Wilke, H.; Muro, K.; Van Cutsem, E.; Oh, S.C.; Bodoky, G.; Shimada, Y.; Hironaka, S.; Sugimoto, N.; Lipatov, O.; Kim, T.Y.; et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomized phase 3 trial. Lancet Oncol. 2014, 15, 1224–1235.
  59. Fuchs, C.S.; Tomasek, J.; Yong, C.J.; Dumitru, F.; Passalacqua, R.; Goswami, C.; Safran, H.; Dos Santos, L.V.; Aprile, G.; Ferry, D.R.; et al. Ramucirumab monotherapy for previously treated advanced gastric or gastroesophageal junction adenocarcinoma (REGARD): An international, randomized, multicenter, placebo-controlled, phase 3 trial. Lancet 2014, 383, 31–39.
  60. Shitara, K.; Özgüroğlu, M.; Bang, Y.J.; Di Bartolomeo, M.; Mandalà, M.; Ryu, M.H.; Fornaro, L.; Olesiński, T.; Caglevic, C.; Chung, H.C.; et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-061): A randomized, open-label, controlled, phase 3 trial. Lancet 2018, 392, 123–133.
  61. Chao, J.; Fuchs, C.S.; Shitara, K.; Tabernero, J.; Muro, K.; Van Cutsem, E.; Bang, Y.J.; De Vita, F.; Landers, G.; Yen, C.J.; et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021, 7, 895–902.
  62. Kang, Y.-K.; Boku, N.; Satoh, T.; Ryu, M.-H.; Chao, Y.; Kato, K.; Chung, H.C.; Chen, J.-S.; Muro, K.; Kang, W.K.; et al. Nivolumab in patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 390, 2461–2471.
  63. Shitara, K.; Doi, T.; Dvorkin, M.; Mansoor, W.; Arkenau, H.T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018, 19, 1437–1448.
  64. Shitara, K.; Bang, Y.J.; Iwasa, S.; Sugimoto, N.; Ryu, M.H.; Sakai, D.; Chung, H.C.; Kawakami, H.; Yabusaki, H.; Lee, J.; et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 2020, 382, 2419–2430.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback